Ascensia receives iCGM designation for Eversense
By HME News Staff
Updated 11:46 AM CDT, Wed May 1, 2024
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings have received an integrated CGM designation from the U.S. Food and Drug Administration. The designation indicates that the Eversense iCGM product can integrate with compatible medical devices, including insulin pumps. “Managing diabetes is all about personal choice and finding the options that best support an individual to live a healthier, less interrupted life,” said Brian Hansen, president of CGM at Ascensia. “For many, one of these choices is to take some of the calculation out of diabetes management by integrating their CGM with an insulin pump as part of an AID system. We are pleased that Eversense has been granted iCGM designation by the FDA, so that people who desire this integration in the future will be able to choose Eversense and access its unique benefits.” The Eversense is an implantable device that lasts six months.
Comments